Skip to main content

Table 1 Associations of PGM5 expression with clinicopathological factors in CRC patients

From: PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients

Variable Number PGM5 level P value
Low High
Age (years) 0.574
 < 65 27 17 (21.5%) 10 (12.7%)  
 ≥ 65 52 36 (45.6%) 16 (20.3%)  
Gender 0.314
 Male 39 25 (31.6%) 14 (17.7%)  
 Female 40 28 (35.4%) 12 (15.2%)  
Tumor size (cm) 0.083
 < 5 27 19 (24.1%) 8 (10.1%)  
 ≥ 5 52 34 (43.0%) 18 (22.8%)  
Lymph node metastasis 0.041
 N0 48 28 (35.4%) 20 (25.3%)  
 N1 22 16 (20.3%) 6 (7.6%)  
 N2 9 9 (11.4%) 0 (24.1%)  
Clinical stage 0.039
 I–II 48 20 (25.3%) 28 (35.4%)  
 III–IV 31 6 (7.6%) 25 (31.6%)  
Survival 0.005
 Live 40 21 (26.6%) 19 (24.1%)  
 Dead 39 32 (40.5%) 7 (8.9%)  
  1. Italic values indicate significance of P value (P < 0.05)
  2. PGM phosphoglucomutase, CRC colorectal cancer